Sab | Jotup

Mark Haden, Psychedelic Medicine Expert, Joins Clearmind Medicine’s Advisory Board

Retrieved on:

Tuesday, August 3, 2021

Toronto, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND) (Clearmind or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, announces that Mark Haden has joined the Companys Scientific Advisory Board (the SAB).

Key Points:

Toronto, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND) (Clearmind or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, announces that Mark Haden has joined the Companys Scientific Advisory Board (the SAB).
A recognized leader in the field, Mr. Haden has spent his career working to advance the use of psychedelics in medicine.
I very much look forward to working with the talented team at Clearmind as well as the other distinguished members of the advisory board.
Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

Inceptor Bio Announces The Appointment Of Dr. Mark J. Gilbert As Chair Of Its Scientific Advisory Board

Retrieved on:

Wednesday, July 28, 2021

Articles, Advisory board, Corporate governance, Board of directors, Sab, Business

He was also a faculty member at the Fred Hutchinson Cancer Center and the University of Washington in Seattle.

Key Points:

He was also a faculty member at the Fred Hutchinson Cancer Center and the University of Washington in Seattle.
As Chair of Inceptor Bio's Scientific Advisory Board, Dr. Gilbert leads an esteemed team of advisors providing guidance on scientific matters to the company's Leadership Team and Board of Directors.
Dr. Gilbert said of his appointment as Chair of Inceptor Bio's Scientific Advisory Board, "After serving on Inceptor Bio's SAB since the company's formation, I'm excited to be appointed the Chair of the Scientific Advisory Board.
An experienced management team, Scientific Advisory Board, and other Directors and strategic advisors offer industry-leading expertise to partnerships.

BioFlyte Forms Scientific Advisory Board of Prominent Government and Life Science Experts

Retrieved on:

Tuesday, July 27, 2021

Health, Defense, Other Health, General Health, Other Defense, Biotechnology, Sab

BioFlyte , a biodetection company with a revolutionary new class of fieldable biological threat collection, detection, and identification solutions, today announced the formation of a Scientific Advisory Board (SAB).

Key Points:

BioFlyte , a biodetection company with a revolutionary new class of fieldable biological threat collection, detection, and identification solutions, today announced the formation of a Scientific Advisory Board (SAB).
We are thrilled to welcome this group of technical advisors to our Scientific Advisory Board, said Charles Call, Ph.D., cofounder and CEO of BioFlyte.
Daniel R. Marshak, Ph.D.: Dr. Daniel R. Marshak is an experienced executive in the Life Science, Biopharmaceutical and Diagnostics industries.
To learn more about BioFlytes Scientific Advisory Board and its technology, please visit https://bioflyte.com .

Asylia Announces Formation of Distinguished Scientific Advisory Board

Retrieved on:

Thursday, July 22, 2021

Sab, Cancer prevention, Immunology

HOUSTON, July 22, 2021 (GLOBE NEWSWIRE) -- Asylia Therapeutics (Asylia), a development-stage biotechnology company advancing novel immune modulating therapies for cancer and autoimmune diseases, today announced the formation of a Scientific Advisory Board (SAB) comprised of prominent experts and thought leaders in immunology and cancer biology.

Key Points:

HOUSTON, July 22, 2021 (GLOBE NEWSWIRE) -- Asylia Therapeutics (Asylia), a development-stage biotechnology company advancing novel immune modulating therapies for cancer and autoimmune diseases, today announced the formation of a Scientific Advisory Board (SAB) comprised of prominent experts and thought leaders in immunology and cancer biology.
The formation of the SAB reflects significant progress with Asylias clinical development strategy as the company advances its lead candidate ASY-77A towards human safety and proof-of-concept studies.
The SAB will provide rigorous scientific review and strategic guidance to Asylias management with regards to its R&D activities and therapeutic portfolio.
Asylia is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas.

Coherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of its Scientific Advisory Board

Retrieved on:

Wednesday, July 21, 2021

Cancer treatments, Clinical medicine, Drugs, Sab, Pembrolizumab

REDWOOD CITY, Calif., July 21, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the appointment of Ildiko Csiki, M.D., Ph.D., a leader in the field of immuno-oncology research and drug development, as Chair of its Scientific Advisory Board (SAB).

Key Points:

REDWOOD CITY, Calif., July 21, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the appointment of Ildiko Csiki, M.D., Ph.D., a leader in the field of immuno-oncology research and drug development, as Chair of its Scientific Advisory Board (SAB).
With Dr. Csiki as Chair, Coherus SAB will work closely with Coherus leadership to build a world-class immuno-oncology franchise that offers life-changing medicines to patients.
We are honored to have Dr. Csiki as Chair of our Scientific Advisory Board.
As a highly regarded and successful physician-scientist, she has made significant contributions to the development of several cancer immunotherapies, including pembrolizumab, said Denny Lanfear, CEO of Coherus.

Big Cypress Acquisition Corp. Reports Ladenburg Conference Presentation by Planned Merger Partner SAB Biotherapeutics

Retrieved on:

Thursday, July 15, 2021

Geography of Florida, Florida, Communication, Forward-looking statement, Big Cypress National Preserve

These statements are based on the current expectations of Big Cypress' management and are not predictions of actual performance.

Key Points:

These statements are based on the current expectations of Big Cypress' management and are not predictions of actual performance.
Many actual events and circumstances are beyond the control of Big Cypress and SAB.
Big Cypress anticipates that subsequent events and developments will cause Big Cypress' assessments to change.
However, while Big Cypress may elect to update these forward-looking statements at some point in the future, Big Cypress specifically disclaims any obligation to do so.

Alberto Mantovani, MD Joins Olatec Therapeutics’ Scientific Advisory Board

Retrieved on:

Thursday, July 8, 2021

Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Sab, Mantovani, Forward-looking statement, Dapansutrile, Olatec Therapeutics LLC, DAPANSUTRILE, OLATEC THERAPEUTICS LLC

Olatec Therapeutics LLC is very pleased to welcome Alberto Mantovani MD to its Scientific Advisory Board.

Key Points:

Olatec Therapeutics LLC is very pleased to welcome Alberto Mantovani MD to its Scientific Advisory Board.
There are few scientists who know and understand IL-1 as much as Alberto.
All of us at Olatec welcome Alberto as a member of our SAB and are looking forward to working with him, stated Damaris B. Skouras, Olatecs CEO and co-Founder.
Any forward-looking statements contained in this release are based on assumptions made by Olatec at the time this Press Release was prepared.

DIACCURATE Introduces Its World-leading Scientific Advisory Board

Retrieved on:

Thursday, July 8, 2021

Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious diseases, Clinical trials, Tasuku Honjo, Sab, Science and technology in Japan, Japanese people

DIACCURATE, a French biotechnology company that develops sole-in-class therapeutics in immunotherapy, oncology and infectiology today announced the formation of its Scientific Advisory Board (SAB).

Key Points:

DIACCURATE, a French biotechnology company that develops sole-in-class therapeutics in immunotherapy, oncology and infectiology today announced the formation of its Scientific Advisory Board (SAB).
Dr. Dominique BRIDON, CEO of DIACCURATE, commented: "We feel honored to have gathered this world-renowned group of experts in our newly formed Scientific Advisory Board around Prof. Jacques THZE, CSO and Scientific co-Founder of DIACCURATE.
DIACCURATE is conducting 3 proprietary development programs and expects to start its first clinical trial by 2022.
DIACCURATE is supported by a high-level management team led by Dr. Dominique BRIDON and world-class Board of Directors and Scientific Advisory Board chaired by Dr. Philippe POULETTY, CEO of TRUFFLE, and Prof. Tasuku HONJO, 2018 Nobel Prize in Medicine.

NEUWAY Pharma Announces Formation of Scientific Advisory Board

Retrieved on:

Tuesday, July 6, 2021

Health, Infectious diseases, Research, Pharmaceutical, Science, Biotechnology, Sab, Pharmaceutical industry in China

NEUWAY Pharma today announced the formation of its Scientific Advisory Board (SAB) including leading drug delivery and drug development experts Hans Grnhagen, Olaf Ritzeler, and Georg Terstappen.

Key Points:

NEUWAY Pharma today announced the formation of its Scientific Advisory Board (SAB) including leading drug delivery and drug development experts Hans Grnhagen, Olaf Ritzeler, and Georg Terstappen.
NEUWAYs SAB will provide scientific guidance and advice as the Company defines its preclinical and early clinical strategies for its proprietary EnPC platform.
We have established our Scientific Advisory Board with these highly distinguished industry experts to support the successful development of our unique technology to deliver therapies to the brain and view their commitment as vote of confidence in our proprietary EnPC delivery approach, stated Oliver Ernst, Ph.D., Managing Director and Chief Operating Officer of NEUWAY Pharma.
NEUWAY Pharma is committed to bringing transformative neuropharmaceuticals across the blood-brain barrier through its proprietary, EnPC protein capsule technology.

Immusoft Announces Formation of Scientific Advisory Board

Retrieved on:

Wednesday, June 23, 2021

Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Other Health, Sab

Immusoft , a cell therapy company dedicated to improving the lives of patients with rare diseases, announced today the formation of its Scientific Advisory Board (SAB) composed of world-renowned experts to provide external scientific review and high-level counsel on the Companys research and development programs.

Key Points:

Immusoft , a cell therapy company dedicated to improving the lives of patients with rare diseases, announced today the formation of its Scientific Advisory Board (SAB) composed of world-renowned experts to provide external scientific review and high-level counsel on the Companys research and development programs.
The SAB will work closely with the Immusoft leadership team to advance and expand its leadership position in B cells as biofactories for therapeutic protein delivery, a novel approach that Immusoft has pioneered.
We look forward to their continued contributions at Immusoft as we enter a new stage in advancing ISP-001 into clinical trials this year."
Members of the Immusoft Scientific Advisory Board are as follows:
Robert Sikorski, M.D., Ph.D., is Head of the SAB and consulting Chief Medical Officer at Immusoft.